VIATRIS INC. Proceeds from Sale of Productive Assets
VIATRIS INC. (VTRS) reported Proceeds from Sale of Productive Assets of $9.80 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfProductiveAssets · last filed 2026-08-06
- VIATRIS INC. proceeds from sale of productive assets for the quarter ending 2026-06-30 was $8.20M, a 412.50% increase year-over-year.
- VIATRIS INC. proceeds from sale of productive assets for the quarter ending 2026-03-31 was $1.60M, a 85.84% decline year-over-year.
- VIATRIS INC. proceeds from sale of productive assets for the quarter ending 2025-09-30 was $800.00K, a 0.00% change year-over-year.
- VIATRIS INC. proceeds from sale of productive assets for the quarter ending 2025-06-30 was $1.60M, a 128.57% increase year-over-year.
| Period end | Proceeds from Sale of Productive Assets 3 month | Proceeds from Sale of Productive Assets 6 month | Proceeds from Sale of Productive Assets 9 month |
|---|---|---|---|
| 2026-06-30 | $8.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $9.80M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $1.60M 10-Q · filed 2026-05-07 | ||
| 2025-09-30 | $800.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.40M derived: sum of 2 quarters · filed 2026-08-06 | $13.70M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $12.90M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $11.30M 10-Q · filed 2026-05-07 | ||
| 2024-09-30 | $800.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.50M derived: sum of 2 quarters · filed 2025-11-06 | $2.20M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $700.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.40M 10-Q · filed 2025-08-07 | |
| 2024-03-31 | $700.00K 10-Q · filed 2025-05-08 | ||
| 2023-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $12.70M derived: sum of 2 quarters · filed 2024-11-07 | $13.40M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $12.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $13.10M 10-Q · filed 2024-08-08 | |
| 2023-03-31 | $700.00K 10-Q · filed 2024-05-09 | ||
| 2022-03-31 | $5.10M 10-Q · filed 2023-05-08 | ||
| 2021-03-31 | $12.50M 10-Q · filed 2022-05-09 | ||
| 2020-03-31 | $400.00K 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |